Alnylam Pharmaceuticals Inc

詳細情報 Alnylam Pharmaceuticals Inc 企業名

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

企業情報

企業コードALNY

会社名Alnylam Pharmaceuticals Inc

上場日May 28, 2004

設立日2003

最高経営責任者「CEO」Dr. Yvonne L. Greenstreet, M.D.

従業員数2230

証券種類Ordinary Share

決算期末May 28

本社所在地675 W Kendall St

都市CAMBRIDGE

証券取引所NASDAQ Global Select Consolidated

国United States of America

郵便番号02142-1168

電話番号16175518200

ウェブサイトhttps://www.alnylam.com/

企業コードALNY

上場日May 28, 2004

設立日2003

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

49.35K

--

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

47.81K

+40.80%

Mr. Tolga Tanguler

Chief Commercial Officer

28.01K

+95.27%

Mr. Michael W. (Mike) Bonney

Chief Compliance Officer, Director

20.80K

+3.87%

Dr. Dennis A. Ausiello, M.D.

Independent Director

4.41K

+21.31%

Dr. Margaret A. Hamburg, M.D.

Independent Director

911.00

+569.85%

Ms. Carolyn R. Bertozzi, M.D.

Independent Director

775.00

--

Dr. Olivier Brandicourt, M.D.

Independent Director

775.00

--

Mr. Peter N. Kellogg

Independent Director

775.00

--

Ms. Colleen F. Reitan

Independent Director

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

49.35K

--

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

47.81K

+40.80%

Mr. Tolga Tanguler

Chief Commercial Officer

28.01K

+95.27%

Mr. Michael W. (Mike) Bonney

Chief Compliance Officer, Director

20.80K

+3.87%

Dr. Dennis A. Ausiello, M.D.

Independent Director

4.41K

+21.31%

Dr. Margaret A. Hamburg, M.D.

Independent Director

911.00

+569.85%

収益内訳

通貨: USD更新時刻: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

事業別USD

会社名

収益

比率

AMVUTTRA

970.45M

43.16%

Regeneron Pharmaceuticals

302.80M

13.47%

GIVLAARI

255.87M

11.38%

ONPATTRO

252.86M

11.25%

OXLUMO

167.05M

7.43%

Other

299.22M

13.31%

地域別USD

会社名

収益

比率

United States

933.54M

41.52%

Europe

516.30M

22.96%

Net revenues from collaborations

510.22M

22.69%

Rest of World

196.39M

8.74%

Royalty revenue

91.79M

4.08%

事業別

地域別

事業別USD

会社名

収益

比率

AMVUTTRA

970.45M

43.16%

Regeneron Pharmaceuticals

302.80M

13.47%

GIVLAARI

255.87M

11.38%

ONPATTRO

252.86M

11.25%

OXLUMO

167.05M

7.43%

Other

299.22M

13.31%

株主

更新時刻: Sat, May 17

株主統計

種類

株主統計

比率

Capital World Investors

12.85%

Fidelity Management & Research Company LLC

11.22%

The Vanguard Group, Inc.

9.97%

Capital Research Global Investors

5.49%

BlackRock Institutional Trust Company, N.A.

5.16%

Other

55.32%

株主統計

比率

Capital World Investors

12.85%

Fidelity Management & Research Company LLC

11.22%

The Vanguard Group, Inc.

9.97%

Capital Research Global Investors

5.49%

BlackRock Institutional Trust Company, N.A.

5.16%

Other

55.32%

種類

株主統計

比率

Investment Advisor

57.08%

Investment Advisor/Hedge Fund

30.90%

Corporation

3.44%

Hedge Fund

3.14%

Sovereign Wealth Fund

2.00%

Research Firm

1.57%

Pension Fund

1.25%

Bank and Trust

1.12%

Individual Investor

0.39%

機関投資家保有株

更新時刻: Sun, Jan 19

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q1

1268

131.09M

100.54%

-4.40M

2024Q4

1263

130.73M

100.99%

-1.47M

2024Q3

1225

126.90M

98.51%

-1.26M

2024Q2

1183

123.30M

96.32%

+1.12M

2024Q1

1172

117.88M

93.23%

-5.46M

2023Q4

1169

120.70M

96.18%

-5.54M

2023Q3

1125

121.55M

96.89%

-6.15M

2023Q2

1119

122.11M

98.30%

-6.32M

2023Q1

1116

123.13M

99.37%

-5.56M

2022Q4

1103

122.98M

99.27%

-3.16M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Capital World Investors

16.60M

12.76%

+92.10K

+0.56%

Dec 31, 2024

Fidelity Management & Research Company LLC

12.94M

9.95%

-1.20M

-8.49%

Dec 31, 2024

The Vanguard Group, Inc.

13.06M

10.04%

+378.83K

+2.99%

Mar 31, 2025

Capital Research Global Investors

6.97M

5.36%

+1.72M

+32.89%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

6.75M

5.19%

+149.81K

+2.27%

Dec 31, 2024

Regeneron Pharmaceuticals Inc

4.44M

3.42%

+4.44M

--

Dec 31, 2024

T. Rowe Price Investment Management, Inc.

4.38M

3.37%

+1.25M

+39.67%

Dec 31, 2024

Baillie Gifford & Co.

4.04M

3.11%

-846.74K

-17.33%

Dec 31, 2024

T. Rowe Price Associates, Inc.

3.23M

2.48%

-123.23K

-3.68%

Dec 31, 2024

State Street Global Advisors (US)

3.42M

2.63%

-45.44K

-1.31%

Dec 31, 2024

詳細を見る

321.940USD

Alnylam Pharmaceuticals Inc

321.940

概要

企業名